Pfizer/Lilly And J&J Are Readying NGF Inhibitors For Phase III
This article was originally published in The Pink Sheet Daily
Executive Summary
Pfizer and Lilly plan to resume Phase III testing of their nerve growth factor inhibitor after FDA lifted a partial hold on tanezumab. But J&J is also poised to run new Phase III studies with fulranumab.
You may also be interested in...
Pfizer/Lilly Discontinue Tanezumab, The Likely End For A Class Dogged By Safety
The nerve growth factor inhibitor for osteoarthritis pain is one of the last still in development after safety largely sidetracked the class of drugs.
Pfizer/Lilly Had Big Ambitions For Tanezumab; Are They Finally Dashed?
Given serious safety questions with tanezumab, the US filing seemed like throwing a Hail Mary; two FDA advisory panels overwhelmingly rejected the proposed risk management plan.
Lilly Shows Off R&D Progress With A Pain Franchise Built On New Mechanisms
With galcanezumab for cluster headaches and migraine and tanezumab for osteoarthritis, lower back pain and cancer pain, Lilly soon could have an up-and-running pain franchise bolstering its long-term, internal R&D strategy.